Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free PSTV Stock Alerts

Plus Therapeutics (PSTV) Financials

Plus Therapeutics logo
$3.90 -0.18 (-4.41%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$3.93 +0.03 (+0.77%)
As of 05:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Plus Therapeutics

Annual Income Statements for Plus Therapeutics

This table shows Plus Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -19 -22 -27 -15 -11 -8.24 -13 -20 -13 -13 -22
Consolidated Net Income / (Loss)		 -19 -22 -23 -13 -11 -8.24 -13 -20 -13 -13 -22
Net Income / (Loss) Continuing Operations		 -19 -22 -23 -8.88 -3.28 -8.24 -13 -20 -13 -13 -22
Total Pre-Tax Income 		-19 -22 -23 -8.41 -5.46 -8.24 -13 -20 -13 -13 -22
Total Operating Income		 -15 -20 -21 -8.76 -3.66 -9.58 -12 -20 -13 -15 -15
Total Gross Profit		 1.65 1.94 0.15 0.00 0.00 0.00 0.00 0.22 4.91 5.82 5.21
Total Revenue		 4.84 4.66 2.69 0.00 0.00 0.00 0.00 0.22 4.91 5.82 5.21
Operating Revenue		 4.84 4.66 2.69 - - - 0.00 0.22 4.91 5.82 5.21
Total Cost of Revenue		 3.19 2.72 2.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 17 22 21 8.76 3.66 9.58 12 20 18 21 21
Selling, General & Admin Expense		 9.77 8.56 7.59 5.58 5.29 6.41 6.85 10 8.54 9.94 12
Research & Development Expense		 12 9.47 13 5.52 5.37 3.48 5.57 9.70 9.69 11 8.38
Total Other Income / (Expense), net		 -3.46 -2.34 -2.00 0.35 -1.80 1.34 -0.91 -0.56 0.01 1.72 -7.09
Interest Expense		 3.64 2.59 2.05 1.92 1.86 1.11 0.93 0.71 0.40 0.18 0.55
Interest & Investment Income		 0.01 0.02 0.03 0.04 0.06 0.05 0.02 0.15 0.40 0.27 0.12
Other Income / (Expense), net		 0.17 0.23 0.01 2.23 - 2.40 0.01 - 0.00 1.62 -6.66
Basic Earnings per Share		 ($2.07) ($1.28) ($8.23) ($86.98) ($8.27) ($1.86) ($1.11) ($11.58) ($4.24) ($1.95) ($0.29)
Weighted Average Basic Shares Outstanding		 9.39M 17.29M 3.24M 173.85K 1.38M 4.43M 12.09M 1.75M 3.14M 6.64M 77.80M
Diluted Earnings per Share		 ($2.07) ($1.28) ($8.23) ($86.98) ($8.27) ($1.86) ($1.11) ($11.58) ($4.24) ($2.34) ($0.29)
Weighted Average Diluted Shares Outstanding		 9.39M 17.29M 3.24M 173.85K 1.38M 4.43M 12.09M 1.75M 3.14M 7.70M 77.80M
Weighted Average Basic & Diluted Shares Outstanding		 9.39M 17.29M 3.24M 173.85K 1.38M 4.43M 12.09M 35.11M 4.28M 17.00M 171.55M

Quarterly Income Statements for Plus Therapeutics

This table shows Plus Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.22 -3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95
Consolidated Net Income / (Loss)		 -3.22 -3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95
Net Income / (Loss) Continuing Operations		 -3.19 -3.85 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95
Total Pre-Tax Income 		-3.22 -3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95
Total Operating Income		 -3.25 -3.86 -3.30 -3.70 -3.80 -3.90 -3.54 -1.54 -4.48 -5.74 -7.12
Total Gross Profit		 1.24 1.31 1.68 1.28 1.46 1.41 1.06 1.39 1.40 1.37 1.03
Total Revenue		 1.24 1.31 1.68 1.28 1.46 1.41 1.06 1.39 1.40 1.37 1.03
Operating Revenue		 1.24 1.31 1.68 1.28 1.46 1.41 1.06 1.39 1.40 1.37 1.03
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 4.49 5.17 4.98 4.98 5.26 5.31 4.60 2.93 5.88 7.11 8.15
Selling, General & Admin Expense		 2.00 2.38 2.21 2.20 2.40 3.13 2.84 1.68 3.44 4.17 5.28
Research & Development Expense		 2.49 2.79 2.76 2.77 2.86 2.19 1.76 1.25 2.44 2.94 2.87
Total Other Income / (Expense), net		 0.03 0.05 0.04 0.76 0.93 -0.00 -14 6.69 0.06 0.03 0.17
Interest Expense		 0.09 0.06 0.03 0.03 0.06 0.06 0.55 0.00 0.00 - 0.02
Interest & Investment Income		 0.12 0.11 0.07 0.07 0.08 0.05 0.00 0.03 0.06 0.03 0.19
Other Income / (Expense), net		 0.00 - 0.00 0.72 0.91 - -13 6.66 0.00 - 0.00
Basic Earnings per Share		 ($1.00) ($1.21) ($0.75) ($0.45) ($0.37) ($0.59) ($29.86) $0.02 ($0.04) $0.92 ($1.05)
Weighted Average Basic Shares Outstanding		 3.23M 3.14M 4.32M 6.50M 7.86M 6.64M 582.67K 48.39M 107.43M 77.80M 6.65M
Diluted Earnings per Share		 ($1.00) ($1.21) ($0.75) ($0.71) ($0.37) ($0.59) ($29.86) ($0.01) ($0.04) $0.95 ($1.05)
Weighted Average Diluted Shares Outstanding		 3.23M 3.14M 4.32M 10.74M 7.86M 7.70M 582.67K 209.15M 107.43M 77.80M 6.65M
Weighted Average Basic & Diluted Shares Outstanding		 4.52M 4.28M - 5.90M 5.90M 17.00M 32.72M 99.26M 137.43M 171.55M 6.88M

Annual Cash Flow Statements for Plus Therapeutics

This table details how cash moves in and out of Plus Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.28 -1.78 -2.69 -4.92 12 -9.25 10 -0.28 -9.57 -8.48 8.68
Net Cash From Operating Activities		 -20 -20 -18 -12 -5.91 -8.43 -10 -13 -13 -11 -21
Net Cash From Continuing Operating Activities		 -20 -20 -18 -12 -5.91 -8.43 -10 -13 -13 -11 -21
Net Income / (Loss) Continuing Operations		 -19 -22 -23 -13 -11 -8.24 -13 -20 -13 -13 -22
Consolidated Net Income / (Loss)		 -19 -22 -23 -13 -11 -8.24 -13 -20 -13 -13 -22
Depreciation Expense		 1.09 1.18 2.15 2.00 0.90 0.37 0.40 0.62 0.63 0.87 0.45
Amortization Expense		 0.98 0.95 0.71 0.58 0.55 0.58 0.57 0.39 0.19 -0.11 -0.01
Non-Cash Adjustments To Reconcile Net Income		 -5.10 1.40 2.74 -0.89 4.47 -1.26 0.92 0.70 0.76 -2.13 7.47
Changes in Operating Assets and Liabilities, net		 1.30 -1.09 -1.04 -1.03 -0.94 0.12 1.24 5.60 -1.12 3.79 -6.29
Net Cash From Investing Activities		 -0.61 0.06 -1.38 -0.13 5.57 -0.49 -0.08 -0.76 -0.16 -4.11 -0.85
Net Cash From Continuing Investing Activities		 -0.61 0.06 -1.38 -0.13 5.57 -0.49 -0.08 -0.76 -0.16 -4.11 -0.85
Purchase of Property, Plant & Equipment		 -0.61 -0.07 -1.50 -0.13 -0.07 -0.09 -0.14 -0.51 -0.16 -0.15 -0.07
Acquisitions		 -0.01 - - - 0.00 -0.40 - - 0.00 -0.55 0.00
Purchase of Investments		 - - - - - - - - 0.00 -16 -9.35
Sale of Property, Plant & Equipment		 0.01 0.13 0.11 - - 0.00 0.06 - - 0.00 0.03
Sale and/or Maturity of Investments		 - - - - - - - - 0.00 12 8.54
Other Investing Activities, net		 - 0.00 - - - - 0.00 -0.25 0.00 0.00 0.00
Net Cash From Financing Activities		 21 18 17 7.17 13 -0.32 20 13 3.45 6.19 30
Net Cash From Continuing Financing Activities		 21 18 17 7.17 13 -0.32 20 13 3.45 6.19 30
Repayment of Debt		 -27 0.00 -4.72 0.00 -3.69 -5.31 -0.27 -1.61 -1.61 -4.00 -9.25
Repurchase of Common Equity		 -2.37 -2.08 -2.08 - 0.00 - 0.00 -0.77 -0.47 -0.37 -0.23
Issuance of Debt		 18 - - - - - - - 0.00 3.29 4.49
Issuance of Common Equity		 29 21 24 0.00 16 4.01 19 16 0.00 0.00 23
Other Financing Activities, net		 3.37 -1.77 0.00 7.17 0.36 0.98 2.01 - 5.53 7.27 13
Cash Interest Paid		 1.99 1.62 1.36 1.33 1.19 0.57 0.39 0.33 0.22 0.03 0.00

Quarterly Cash Flow Statements for Plus Therapeutics

This table details how cash moves in and out of Plus Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 0.11 -2.45 -5.65 2.01 -3.69 -1.15 9.79 -7.63 11 -4.53 -5.74
Net Cash From Operating Activities		 -2.40 -1.88 -4.51 -1.15 -3.68 -1.21 -6.17 -5.80 -2.55 -6.26 -6.24
Net Cash From Continuing Operating Activities		 -2.40 -1.88 -4.51 -1.15 -3.68 -1.21 -6.17 -5.80 -2.55 -6.26 -6.24
Net Income / (Loss) Continuing Operations		 -3.22 -3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95
Consolidated Net Income / (Loss)		 -3.22 -3.81 -3.26 -2.94 -2.87 -3.90 -17 5.15 -4.42 -5.71 -6.95
Depreciation Expense		 0.16 0.15 0.16 0.17 0.20 0.35 0.15 0.08 0.08 0.15 0.10
Amortization Expense		 0.07 -0.06 0.02 -0.02 -0.05 -0.06 0.04 -0.02 0.00 0.01 -0.01
Non-Cash Adjustments To Reconcile Net Income		 -0.59 0.35 0.18 -0.97 -0.80 -0.54 13 -7.52 0.99 0.91 0.01
Changes in Operating Assets and Liabilities, net		 1.18 1.49 -1.60 2.61 -0.16 2.94 -2.01 -3.48 0.81 -1.61 0.61
Net Cash From Investing Activities		 -0.01 -0.04 -0.36 -3.80 -0.01 0.06 3.56 -4.63 1.30 -1.08 -8.53
Net Cash From Continuing Investing Activities		 -0.01 -0.04 -0.36 -3.80 -0.01 0.06 3.56 -4.63 1.30 -1.08 -8.53
Purchase of Property, Plant & Equipment		 -0.01 -0.04 -0.04 -0.08 -0.01 -0.01 -0.00 -0.01 -0.03 -0.03 -0.82
Acquisitions		 - - - - - - 0.00 - -0.01 0.01 0.00
Purchase of Investments		 - - - - -3.65 -8.45 0.00 - -3.31 1.72 -9.70
Sale of Property, Plant & Equipment		 - - 0.00 - - - 0.03 - - - 0.00
Sale and/or Maturity of Investments		 - - -0.32 0.32 3.65 8.52 3.53 3.13 4.64 -2.77 1.99
Net Cash From Financing Activities		 2.52 -0.53 -0.78 6.96 - - 12 2.80 12 2.80 9.04
Net Cash From Continuing Financing Activities		 2.52 -0.53 -0.78 6.96 - - 12 2.80 12 2.80 9.04
Repayment of Debt		 -0.40 -0.40 -0.40 -3.59 - - -7.00 - -2.25 - -1.10
Repurchase of Common Equity		 - -0.47 -0.37 -0.05 0.05 - 0.00 -0.22 -0.01 - -1.36
Issuance of Debt		 - - 0.00 3.29 - - 3.74 - - 0.75 1.00
Issuance of Common Equity		 -2.26 - 0.00 - - - 0.00 -12 17 3.00 0.00
Other Financing Activities, net		 - 0.35 0.00 7.31 -0.05 - 16 15 -2.25 -0.95 10
Cash Interest Paid		 0.05 0.04 0.02 0.01 - - 0.54 0.54 - -0.54 0.00

Annual Balance Sheets for Plus Therapeutics

This table presents Plus Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 38 35 32 24 23 12 22 24 11 6.63 16
Total Current Assets		 21 19 15 9.65 20 9.18 20 22 9.83 5.26 15
Cash & Equivalents		 14 13 9.55 5.26 18 8.35 18 18 8.55 0.08 4.26
Restricted Cash		 0.00 0.35 0.68 0.04 0.04 - - - - 0.00 4.50
Short-Term Investments		 - - - - - - - - 0.00 3.53 4.36
Other Current Assets		 1.56 0.87 1.31 0.79 0.96 0.83 1.32 3.70 1.28 1.65 2.06
Plant, Property, & Equipment, net		 1.63 1.16 3.05 2.30 2.18 1.82 1.48 1.32 0.91 0.45 0.26
Total Noncurrent Assets		 15 15 14 12 1.23 1.11 0.78 0.73 0.65 0.93 0.90
Goodwill		 3.92 3.92 3.92 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37
Intangible Assets		 9.03 8.45 7.21 - 0.00 0.09 0.05 0.09 0.04 0.47 0.33
Other Noncurrent Operating Assets		 1.52 2.34 2.57 0.04 0.85 0.65 0.36 0.26 0.23 0.09 0.19
Total Liabilities & Shareholders' Equity		 38 35 32 24 23 12 22 24 11 6.63 16
Total Liabilities		 25 24 19 19 22 9.07 11 17 13 16 12
Total Current Liabilities		 8.44 13 18 18 14 8.54 5.87 12 11 16 12
Short-Term Debt		 0.00 6.63 14 14 11 6.34 1.61 1.61 3.98 3.29 0.75
Accounts Payable		 6.69 5.87 4.79 2.78 3.28 2.08 4.15 10 6.63 11 5.92
Current Deferred Revenue		 - - - - - - - - 0.00 0.93 0.93
Other Current Liabilities		 1.75 - - - 0.15 0.12 0.11 0.11 0.12 0.04 4.72
Total Noncurrent Liabilities		 17 11 0.20 1.21 7.58 0.54 5.28 5.57 2.01 0.03 0.02
Other Noncurrent Operating Liabilities		 - - - 0.96 7.58 0.54 0.27 1.78 2.01 0.03 0.02
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 12 11 13 5.23 1.16 3.03 11 6.45 -1.35 -8.95 4.00
Total Preferred & Common Equity		 12 11 13 5.23 1.16 3.03 11 6.45 -1.35 -8.95 4.00
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 12 11 13 5.23 1.16 3.03 11 6.45 -1.35 -8.95 4.00
Common Stock		 368 389 413 418 426 437 458 474 479 485 520
Retained Earnings		 -357 -379 -402 -414 -425 -434 -447 -467 -481 -493 -516
Treasury Stock		 - - - - - - - 0.00 -0.13 -0.50 -0.50

Quarterly Balance Sheets for Plus Therapeutics

This table presents Plus Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 13 5.62 11 6.98 12 10 19 20
Total Current Assets		 12 4.21 9.38 5.36 11 9.21 18 18
Cash & Equivalents		 11 2.90 4.91 1.22 9.87 2.23 13 3.02
Restricted Cash		 - - - - - - - 0.00
Short-Term Investments		 - 0.32 3.52 3.57 0.00 4.65 3.31 12
Other Current Assets		 0.58 0.99 0.95 0.58 1.00 2.34 0.99 2.91
Plant, Property, & Equipment, net		 1.01 0.80 0.73 0.59 0.32 0.29 0.27 1.01
Total Noncurrent Assets		 0.69 0.61 1.10 1.02 0.86 0.85 0.81 0.88
Goodwill		 0.37 0.37 0.37 0.37 0.37 0.37 0.37 0.37
Intangible Assets		 0.05 0.03 0.56 0.51 0.44 0.40 0.37 0.30
Other Noncurrent Operating Assets		 0.26 0.20 0.17 0.14 0.06 0.07 0.07 0.20
Total Liabilities & Shareholders' Equity		 13 5.62 11 6.98 12 10 19 20
Total Liabilities		 11 10 19 12 36 7.32 14 7.96
Total Current Liabilities		 11 10 19 12 11 7.32 14 7.96
Short-Term Debt		 4.35 3.59 3.29 3.29 0.00 0.00 0.00 0.67
Accounts Payable		 6.07 6.45 6.95 7.91 9.22 6.36 12 6.16
Current Deferred Revenue		 - 0.25 2.30 0.84 1.30 0.93 1.97 0.93
Other Current Liabilities		 0.12 0.12 6.25 0.07 0.04 0.03 0.02 0.20
Total Noncurrent Liabilities		 0.12 0.06 0.05 0.04 25 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 0.12 0.06 0.05 0.04 25 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2.62 -4.84 -7.63 -5.17 -24 3.03 5.05 12
Total Preferred & Common Equity		 2.62 -4.84 -7.63 -5.17 -24 3.03 5.05 12
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2.62 -4.84 -7.63 -5.17 -24 3.03 5.05 12
Common Stock		 479 479 480 485 488 509 516 535
Retained Earnings		 -477 -484 -487 -490 -511 -506 -510 -523
Treasury Stock		 - -0.50 -0.50 -0.50 -0.50 -0.50 -0.50 -0.50

Annual Metrics And Ratios for Plus Therapeutics

This table displays calculated financial ratios and metrics derived from Plus Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 158,458,195.00 20,500,553.00 35,119,410.00 13,201,410.00 3,770,588.00 4,779,584.00 15,360,025.00 33,601,373.00 4,522,656.00 5,896,333.00 137,429,055.00
DEI Adjusted Shares Outstanding		 1,409.00 2,733.00 4,683.00 17,602.00 251,373.00 318,639.00 1,024,002.00 2,240,092.00 4,522,656.00 235,853.00 5,497,162.00
DEI Earnings Per Adjusted Shares Outstanding		 -13,772.18 -8,066.59 -5,693.57 -859.05 -45.51 -25.86 -13.08 -9.05 -2.94 -55.03 -4.07
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -2.32% -3.76% -42.25% -100.00% 0.00% 0.00% 0.00% 0.00% 2,093.30% 18.54% -10.49%
EBITDA Growth		 57.93% -32.93% -2.74% 77.84% 43.98% -181.95% -84.81% -62.35% 33.15% 1.54% -74.79%
EBIT Growth		 54.20% -28.84% -6.15% 68.41% 43.99% -96.45% -73.80% -57.87% 32.42% 1.87% -67.95%
NOPAT Growth		 52.87% -28.92% -4.96% 57.64% 58.26% -162.07% -30.34% -57.80% 32.42% -10.31% -4.10%
Net Income Growth		 49.84% -17.62% -2.90% 44.31% 13.83% 24.30% -62.59% -51.32% 34.32% 2.54% -72.49%
EPS Growth		 49.84% 38.16% -2.90% 44.31% 90.49% 77.51% 40.32% -51.32% 63.39% 44.81% 87.61%
Operating Cash Flow Growth		 32.52% 4.57% 7.19% 33.94% 50.68% -42.80% -21.89% -26.19% 0.93% 17.87% -96.84%
Free Cash Flow Firm Growth		 -45.43% 24.10% 0.94% 167.43% -72.10% -559.18% 48.30% -25.02% -14.30% 28.21% -66.97%
Invested Capital Growth		 200.19% 10.66% 4.37% -99.75% -13,202.44% 118.99% -193.24% -560.46% 5.65% -56.31% 9.66%
Revenue Q/Q Growth		 -15.88% -1.90% -23.02% -100.00% 100.00% 0.00% 0.00% 206.85% 30.98% 1.73% -0.86%
EBITDA Q/Q Growth		 17.11% -14.46% 2.55% 49.00% -1,105.00% 15.60% -4.58% -10.27% 11.57% 12.59% -9.38%
EBIT Q/Q Growth		 14.72% -12.87% 2.06% 36.28% -122.18% 14.49% -4.50% -9.03% 11.40% 10.79% -9.16%
NOPAT Q/Q Growth		 12.77% -8.30% -0.20% 27.32% -105.22% -14.08% -4.55% -9.03% 11.40% -0.29% -13.69%
Net Income Q/Q Growth		 13.77% -10.83% 2.71% 13.96% 22.27% -118.59% -4.43% -8.01% 12.19% -0.72% -8.80%
EPS Q/Q Growth		 13.77% -31.96% 2.71% 13.96% 53.06% -100.00% -18.09% -8.01% 9.79% -42.68% -52.63%
Operating Cash Flow Q/Q Growth		 2.08% 1.81% -0.35% 12.66% 37.37% -102.06% 5.51% 2.92% 2.67% 5.97% -32.08%
Free Cash Flow Firm Q/Q Growth		 -37,883.43% 42.07% -2.74% 281.50% -84.00% -2.08% 8.65% 8.77% -0.47% 8.84% -155.46%
Invested Capital Q/Q Growth		 574.86% -0.51% 1.83% -99.69% 7.01% -13.27% -518.94% -99.65% -46.83% -38.88% 27.53%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 34.15% 41.69% 5.43% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -269.57% -372.36% -662.40% 0.00% 0.00% 0.00% 0.00% -8,350.00% -254.49% -211.38% -412.78%
Operating Margin		 -315.96% -423.24% -769.17% 0.00% 0.00% 0.00% 0.00% -8,800.00% -271.14% -252.32% -293.46%
EBIT Margin		 -312.40% -418.23% -768.69% 0.00% 0.00% 0.00% 0.00% -8,800.00% -271.14% -224.45% -421.14%
Profit (Net Income) Margin		 -387.43% -473.50% -843.66% 0.00% 0.00% 0.00% 0.00% -9,051.34% -271.04% -222.84% -429.43%
Tax Burden Percent		 100.00% 100.00% 100.00% 150.26% 199.51% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 124.02% 113.21% 109.75% 128.78% 149.22% 114.71% 107.31% 102.86% 99.96% 99.28% 101.97%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -113.06% -92.23% -90.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -242.53% -337.82% -292.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -463.33% -97.89% -98.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -576.38% -190.12% -189.16% -138.64% -341.02% -393.27% -193.25% -234.65% -522.50% 252.07% 903.94%
Cash Return on Invested Capital (CROIC)		 -213.10% -102.35% -94.45% 124.39% 0.00% -1,284.39% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -39.56% -53.86% -62.42% 0.00% 0.00% 0.00% 0.00% -85.99% -75.57% -145.08% -191.25%
Return on Assets (ROA)		 -49.06% -60.98% -68.51% 0.00% 0.00% 0.00% 0.00% -88.44% -75.54% -144.03% -195.02%
Return on Common Equity (ROCE)		 -576.38% -190.12% -189.16% -138.64% -341.02% -393.27% -193.25% -234.65% -522.50% 252.07% 903.94%
Return on Equity Simple (ROE_SIMPLE)		 -153.56% -200.67% -174.51% -241.80% -938.53% -271.89% -123.65% -314.58% 987.83% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -14 -14 -6.13 -2.56 -6.71 -8.74 -14 -9.32 -10 -11
NOPAT Margin		 -221.17% -296.27% -538.42% 0.00% 0.00% 0.00% 0.00% -6,160.00% -189.80% -176.62% -205.42%
Net Nonoperating Expense Percent (NNEP)		 129.48% 245.59% 202.02% -728.36% -142.15% -35.87% -67.47% -52.84% -46.13% -110.04% -184.22%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -354.82% 181.84% -225.63%
Cost of Revenue to Revenue		 65.85% 58.31% 94.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 201.84% 183.91% 282.41% 0.00% 0.00% 0.00% 0.00% 4,570.54% 173.91% 170.66% 232.73%
R&D to Revenue		 251.74% 203.46% 496.99% 0.00% 0.00% 0.00% 0.00% 4,329.46% 197.23% 181.66% 160.73%
Operating Expenses to Revenue		 350.10% 464.93% 774.60% 0.00% 0.00% 0.00% 0.00% 8,900.00% 371.14% 352.32% 393.46%
Earnings before Interest and Taxes (EBIT)		 -15 -19 -21 -6.53 -3.66 -7.18 -12 -20 -13 -13 -22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -13 -17 -18 -3.95 -2.21 -6.23 -12 -19 -13 -12 -22
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.40 2.82 0.81 0.73 7.80 3.19 1.49 1.65 0.00 0.00 17.62
Price to Tangible Book Value (P/TBV)		 0.00 0.00 5.66 0.79 11.48 3.75 1.55 1.78 0.00 0.00 21.39
Price to Revenue (P/Rev)		 6.06 6.65 3.94 0.00 0.00 0.00 0.00 47.55 1.61 1.16 13.51
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.23 2.27 0.85 310.47 0.00 7.49 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 6.54 7.66 5.20 0.00 0.00 0.00 0.00 0.00 0.68 1.11 11.13
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 1.25 0.88 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.37 1.61 1.05 2.72 9.53 2.09 0.61 0.84 -2.95 -0.37 0.19
Long-Term Debt to Equity		 1.37 1.00 0.00 0.00 0.00 0.00 0.46 0.59 0.00 0.00 0.00
Financial Leverage		 1.91 0.29 0.34 -0.10 -1.83 -2.04 -1.00 -1.42 -3.39 0.48 2.56
Leverage Ratio		 11.75 3.12 2.76 3.05 7.40 8.43 2.46 2.65 6.92 -1.75 -4.64
Compound Leverage Factor		 14.57 3.53 3.03 3.93 11.04 9.67 2.64 2.73 6.91 -1.74 -4.73
Debt to Total Capital		 57.75% 61.62% 51.17% 73.10% 90.51% 67.64% 37.90% 45.56% 151.29% -58.19% 15.80%
Short-Term Debt to Total Capital		 0.00% 23.16% 51.17% 73.10% 90.51% 67.64% 9.22% 13.58% 151.29% -58.19% 15.80%
Long-Term Debt to Total Capital		 57.75% 38.46% 0.00% 0.00% 0.00% 0.00% 28.68% 31.98% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 42.25% 38.38% 48.83% 26.90% 9.49% 32.36% 62.10% 54.44% -51.29% 158.19% 84.20%
Debt to EBITDA		 -1.28 -1.02 -0.76 -3.60 -5.00 -1.02 -0.57 -0.29 -0.32 -0.27 -0.03
Net Debt to EBITDA		 -0.18 -0.27 -0.19 -2.26 2.95 0.32 1.02 0.68 0.37 0.03 0.57
Long-Term Debt to EBITDA		 -1.28 -0.63 0.00 0.00 0.00 0.00 -0.43 -0.20 0.00 0.00 0.00
Debt to NOPAT		 -1.56 -1.28 -0.94 -2.32 -4.32 -0.94 -0.76 -0.39 -0.43 -0.32 -0.07
Net Debt to NOPAT		 -0.22 -0.34 -0.23 -1.45 2.55 0.30 1.35 0.92 0.49 0.03 1.15
Long-Term Debt to NOPAT		 -1.56 -0.80 0.00 0.00 0.00 0.00 -0.57 -0.27 0.00 0.00 0.00
Altman Z-Score		 -13.36 -16.05 -19.66 -25.35 -25.63 -51.39 -28.71 -29.25 -62.22 -111.38 -44.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.52 1.50 0.81 0.55 1.37 1.07 3.36 1.84 0.92 0.34 1.23
Quick Ratio		 1.82 1.10 0.53 0.31 1.29 0.98 3.13 1.53 0.80 0.23 0.70
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -20 -15 -15 10 2.85 -13 -6.77 -8.47 -9.68 -6.95 -12
Operating Cash Flow to CapEx		 -3,411.33% 0.00% -1,310.77% -9,003.76% -8,814.93% -9,068.82% -12,536.59% -2,548.53% -8,031.88% -7,228.77% -56,148.65%
Free Cash Flow to Firm to Interest Expense		 -5.54 -5.91 -7.40 5.32 1.54 -11.83 -7.27 -11.91 -24.51 -38.82 -21.17
Operating Cash Flow to Interest Expense		 -5.62 -7.54 -8.85 -6.23 -3.18 -7.62 -11.03 -18.24 -32.53 -58.96 -37.91
Operating Cash Flow Less CapEx to Interest Expense		 -5.79 -7.51 -9.52 -6.30 -3.22 -7.70 -11.12 -18.96 -32.94 -59.78 -37.98
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.13 0.13 0.08 0.00 0.00 0.00 0.00 0.01 0.28 0.65 0.45
Accounts Receivable Turnover		 4.22 4.06 3.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.70 0.68 0.74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.01 3.34 1.28 0.00 0.00 0.00 0.00 0.16 4.41 8.60 14.79
Accounts Payable Turnover		 0.52 0.43 0.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 86.57 89.92 94.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 522.81 539.30 495.76 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 700.73 844.21 765.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -91.35 -214.99 -175.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 14 16 16 0.04 -5.37 1.02 -0.95 -6.28 -5.93 -9.26 -8.37
Invested Capital Turnover		 0.51 0.31 0.17 0.00 0.00 0.00 0.00 -0.06 -0.80 -0.77 -0.59
Increase / (Decrease) in Invested Capital		 9.47 1.51 0.69 -16 -5.41 6.39 -1.97 -5.33 0.36 -3.34 0.90
Enterprise Value (EV)		 32 36 14 13 2.52 7.64 4.34 -2.07 3.34 6.47 58
Market Capitalization		 29 31 11 3.83 9.05 9.65 16 11 7.92 6.78 70
Book Value per Share		 $0.08 $0.54 $0.37 $0.40 $0.31 $0.63 $0.71 $0.19 ($0.30) ($1.52) $0.03
Tangible Book Value per Share		 $0.00 ($0.07) $0.05 $0.37 $0.21 $0.54 $0.68 $0.18 ($0.39) ($1.66) $0.02
Total Capital		 29 29 27 19 12 9.37 17 12 2.63 -5.66 4.75
Total Debt		 17 18 14 14 11 6.34 6.61 5.39 3.98 3.29 0.75
Total Long-Term Debt		 17 11 0.00 0.00 0.00 0.00 5.01 3.79 0.00 0.00 0.00
Net Debt		 2.34 4.73 3.40 8.90 -6.53 -2.01 -12 -13 -4.58 -0.31 -12
Capital Expenditures (CapEx)		 0.60 -0.06 1.38 0.13 0.07 0.09 0.08 0.51 0.16 0.15 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.53 -0.04 -0.15 0.99 -1.19 -1.38 -2.94 -6.55 -5.47 -11 -9.51
Debt-free Net Working Capital (DFNWC)		 13 13 10 6.29 16 6.97 15 12 3.08 -7.00 3.61
Net Working Capital (NWC)		 13 6.25 -3.55 -7.91 5.34 0.64 14 9.97 -0.89 -10 2.86
Net Nonoperating Expense (NNE)		 8.04 8.25 8.21 6.50 8.33 1.53 4.65 6.48 3.99 2.69 12
Net Nonoperating Obligations (NNO)		 1.99 4.73 3.40 -5.18 -6.53 -2.01 -12 -13 -4.58 -0.31 -12
Total Depreciation and Amortization (D&A)		 2.07 2.14 2.86 2.58 1.45 0.95 0.97 1.01 0.82 0.76 0.44
Debt-free, Cash-free Net Working Capital to Revenue		 -31.67% -0.75% -5.62% 0.00% 0.00% 0.00% 0.00% -2,922.77% -111.36% -182.11% -182.39%
Debt-free Net Working Capital to Revenue		 264.70% 276.52% 374.64% 0.00% 0.00% 0.00% 0.00% 5,166.52% 62.75% -120.19% 69.17%
Net Working Capital to Revenue		 264.70% 134.15% -132.02% 0.00% 0.00% 0.00% 0.00% 4,448.66% -18.18% -176.72% 54.79%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($15,750.00) ($9,600.00) ($6,150.00) ($1,305.00) ($124.05) ($27.90) ($16.65) ($11.55) ($4.24) ($48.75) ($7.25)
Adjusted Weighted Average Basic Shares Outstanding		 1.74K 2.93K 7.98K 21.77K 258.71K 1.41M 1.48M 1.75M 3.14M 265.61K 3.11M
Adjusted Diluted Earnings per Share		 ($15,750.00) ($9,600.00) ($6,150.00) ($1,305.00) ($124.05) ($27.90) ($16.65) ($11.55) ($4.24) ($58.50) ($7.25)
Adjusted Weighted Average Diluted Shares Outstanding		 1.74K 2.93K 7.98K 21.77K 258.71K 1.41M 1.48M 1.75M 3.14M 308.03K 3.11M
Adjusted Basic & Diluted Earnings per Share		 ($15,750.00) ($9,600.00) ($6,150.00) ($1,305.00) ($124.05) ($27.90) ($16.65) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.25K 2.31K 4.32K 11.59K 92.27K 295.19K 805.95K 2.34M 4.28M 679.99K 6.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -14 -14 -6.13 -2.56 -6.71 -8.70 -14 -9.32 -10 -11
Normalized NOPAT Margin		 -221.17% -296.27% -538.42% 0.00% 0.00% 0.00% 0.00% -6,160.00% -189.80% -176.62% -205.42%
Pre Tax Income Margin		 -387.43% -473.50% -843.66% 0.00% 0.00% 0.00% 0.00% -9,051.79% -271.04% -222.84% -429.43%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -4.15 -7.51 -10.09 -3.40 -1.97 -6.49 -13.40 -27.72 -33.72 -73.03 -40.06
NOPAT to Interest Expense		 -2.94 -5.32 -7.07 -3.19 -1.38 -6.06 -9.38 -19.41 -23.61 -57.47 -19.54
EBIT Less CapEx to Interest Expense		 -4.32 -7.49 -10.76 -3.47 -2.01 -6.57 -13.49 -28.44 -34.13 -73.84 -40.13
NOPAT Less CapEx to Interest Expense		 -3.11 -5.30 -7.74 -3.26 -1.42 -6.14 -9.47 -20.12 -24.01 -58.28 -19.61
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -0.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -13.04% -9.45% -9.16% 0.00% 0.00% 0.00% 0.00% -3.81% -3.56% -2.88% -1.03%

Quarterly Metrics And Ratios for Plus Therapeutics

This table displays calculated financial ratios and metrics derived from Plus Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 2,879,620.00 4,522,656.00 4,276,082.00 4,276,082.00 5,896,333.00 5,896,333.00 16,999,626.00 32,717,054.00 99,264,526.00 137,429,055.00 171,550,698.00
DEI Adjusted Shares Outstanding		 2,879,620.00 4,522,656.00 4,276,082.00 4,276,082.00 5,896,333.00 235,853.00 679,985.00 32,717,054.00 99,264,526.00 5,497,162.00 6,862,028.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.12 -0.84 -0.76 -0.69 -0.49 -16.55 -25.59 0.16 -0.04 -1.04 -1.01
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 1,598.63% 769.54% 231.42% -31.01% 17.42% 7.54% -36.85% 8.68% -4.05% -3.19% -2.93%
EBITDA Growth		 37.26% 30.30% 30.48% -131.97% 9.30% 3.99% -433.19% 283.00% -60.60% -54.64% 57.83%
EBIT Growth		 36.18% 30.76% 30.14% -100.00% 11.01% -1.09% -410.88% 271.95% -54.93% -47.23% 57.76%
NOPAT Growth		 36.18% 30.76% 30.14% -148.12% -16.86% -1.09% -7.18% 40.57% -17.98% -47.23% -101.33%
Net Income Growth		 38.32% 32.66% 32.13% -98.38% 10.72% -2.44% -433.61% 275.20% -53.90% -46.37% 60.08%
EPS Growth		 64.91% 62.54% 63.77% -20.34% 63.00% 51.24% -433.61% 98.59% 89.19% 261.02% 60.08%
Operating Cash Flow Growth		 43.18% 15.80% 22.10% 58.60% -53.40% 35.62% -36.76% -404.17% 30.76% -416.68% -1.07%
Free Cash Flow Firm Growth		 -618.72% -313.74% -300.08% 6,761.96% 98.17% 119.87% 1,039.14% -257.16% 6,975.89% -909.62% -235.55%
Invested Capital Growth		 -28.29% 5.65% 10.40% -262.32% -65.26% -56.31% -649.45% 69.89% -73.12% 9.66% 92.58%
Revenue Q/Q Growth		 -33.12% 5.89% 27.72% -23.73% 13.84% -3.02% -25.00% 31.26% 0.50% -2.15% -24.80%
EBITDA Q/Q Growth		 -147.70% -24.52% 16.90% 9.50% 3.14% -31.81% -361.47% 131.00% -185.00% -26.92% -25.85%
EBIT Q/Q Growth		 -118.19% -18.67% 14.49% 9.67% 2.92% -34.81% -332.15% 130.40% -187.47% -28.11% -23.98%
NOPAT Q/Q Growth		 -118.19% -18.67% 14.49% -12.06% -2.76% -2.66% 9.33% 37.86% -103.99% -28.11% -23.98%
Net Income Q/Q Growth		 -117.21% -18.36% 14.41% 9.84% 2.24% -35.80% -345.84% 129.60% -185.87% -29.17% -21.58%
EPS Q/Q Growth		 -69.49% -21.00% 38.02% 5.33% 47.89% -59.46% -345.84% 99.16% -300.00% 2,475.00% -21.58%
Operating Cash Flow Q/Q Growth		 13.64% 21.59% -139.93% 74.52% -220.00% 67.09% -409.66% 6.06% 56.05% -145.57% 0.30%
Free Cash Flow Firm Q/Q Growth		 -1,528.56% -120.51% 7.44% 335.34% -100.38% 2,499.21% 4,275.91% -139.38% 116.63% -382.50% -632.65%
Invested Capital Q/Q Growth		 -14.53% -46.83% 24.55% -185.57% 47.76% -38.88% -261.74% 88.53% -200.31% 27.53% 70.29%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -243.71% -286.60% -186.46% -221.27% -188.26% -255.88% -1,574.41% 372.59% -315.10% -408.71% -683.95%
Operating Margin		 -262.18% -293.83% -196.72% -289.05% -260.92% -276.20% -333.90% -110.65% -320.83% -420.04% -692.51%
EBIT Margin		 -262.18% -293.83% -196.72% -232.99% -198.70% -276.20% -1,591.50% 368.63% -320.83% -420.04% -692.51%
Profit (Net Income) Margin		 -259.60% -290.18% -194.45% -229.87% -197.39% -276.42% -1,643.15% 370.58% -316.61% -417.92% -675.68%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.02% 98.76% 98.85% 98.66% 99.34% 100.08% 103.25% 100.53% 98.68% 99.49% 97.57%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -216.23% -522.50% 1,089.50% 533.15% 1,009.80% 252.07% 190.45% 828.88% 34,293.33% 903.94% 204.30%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -54.06% -81.89% -112.60% -101.03% -112.32% -178.53% -937.42% 181.80% -131.54% -190.76% -224.48%
Return on Assets (ROA)		 -53.53% -80.88% -111.30% -99.68% -111.58% -178.66% -967.84% 182.76% -129.81% -189.79% -219.03%
Return on Common Equity (ROCE)		 -216.23% -522.50% 1,089.50% 533.15% 1,009.80% 252.07% 190.45% 828.88% 34,293.33% 903.94% 204.30%
Return on Equity Simple (ROE_SIMPLE)		 -578.34% 0.00% 243.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.28 -2.70 -2.31 -2.59 -2.66 -2.73 -2.48 -1.54 -3.14 -4.02 -4.98
NOPAT Margin		 -183.52% -205.68% -137.70% -202.34% -182.64% -193.34% -233.73% -110.65% -224.58% -294.03% -484.76%
Net Nonoperating Expense Percent (NNEP)		 -8.90% -12.82% -26.07% -6.22% -5.27% -47.96% -314.19% 111.28% -14.21% -26.72% -16.14%
Return On Investment Capital (ROIC_SIMPLE)		 - -102.76% 185.19% 59.73% 141.30% 48.26% 10.47% -50.69% -62.08% -84.69% -39.46%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 161.13% 181.04% 131.96% 172.24% 164.63% 221.39% 268.08% 121.01% 246.46% 304.90% 513.81%
R&D to Revenue		 201.05% 212.80% 164.76% 216.81% 196.29% 154.82% 165.82% 89.64% 174.37% 215.14% 278.70%
Operating Expenses to Revenue		 362.18% 393.83% 296.72% 389.05% 360.92% 376.20% 433.90% 210.65% 420.83% 520.04% 792.51%
Earnings before Interest and Taxes (EBIT)		 -3.25 -3.86 -3.30 -2.98 -2.89 -3.90 -17 5.12 -4.48 -5.74 -7.12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.02 -3.76 -3.13 -2.83 -2.74 -3.61 -17 5.18 -4.40 -5.59 -7.03
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.47 0.00 0.00 0.00 0.00 0.00 0.00 3.75 13.43 17.62 2.33
Price to Tangible Book Value (P/TBV)		 1.75 0.00 0.00 0.00 0.00 0.00 0.00 5.03 15.75 21.39 2.47
Price to Revenue (P/Rev)		 1.03 1.61 1.27 1.14 1.50 1.16 3.10 2.14 12.91 13.51 5.38
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.68 1.33 0.21 1.24 1.11 1.21 0.85 9.75 11.13 2.60
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.34 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.66 -2.95 -0.74 -0.43 -0.64 -0.37 0.00 0.00 0.00 0.19 0.06
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.51 -3.39 3.38 2.28 3.20 0.48 0.33 2.62 150.81 2.56 2.08
Leverage Ratio		 2.59 6.92 -9.84 -5.12 -7.94 -1.75 -0.62 -4.70 -213.73 -4.64 -2.74
Compound Leverage Factor		 2.57 6.83 -9.72 -5.05 -7.89 -1.75 -0.64 -4.72 -210.92 -4.61 -2.67
Debt to Total Capital		 62.38% 151.29% -287.89% -75.98% -174.92% -58.19% 0.00% 0.00% 0.00% 15.80% 5.28%
Short-Term Debt to Total Capital		 62.38% 151.29% -287.89% -75.98% -174.92% -58.19% 0.00% 0.00% 0.00% 15.80% 5.28%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 37.62% -51.29% 387.89% 175.98% 274.92% 158.19% 100.00% 100.00% 100.00% 84.20% 94.72%
Debt to EBITDA		 -0.31 -0.32 -0.32 -0.24 -0.23 -0.27 0.00 0.00 0.00 -0.03 -0.06
Net Debt to EBITDA		 0.47 0.37 -0.03 0.38 0.11 0.03 0.00 0.00 0.00 0.57 1.22
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.41 -0.43 -0.43 -0.33 -0.32 -0.32 0.00 0.00 0.00 -0.07 -0.05
Net Debt to NOPAT		 0.63 0.49 -0.04 0.52 0.15 0.03 0.00 0.00 0.00 1.15 1.09
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -50.47 -59.48 -122.22 -61.97 -99.51 -106.82 -63.21 -65.11 -35.52 -41.44 -34.96
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.10 0.92 0.41 0.50 0.44 0.34 1.03 1.26 1.29 1.23 2.27
Quick Ratio		 1.04 0.80 0.31 0.45 0.40 0.23 0.93 0.94 1.22 0.70 1.90
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.39 -3.06 -2.83 6.66 -0.03 0.61 27 -10 1.74 -4.91 -36
Operating Cash Flow to CapEx		 -23,990.00% -4,478.57% -11,282.50% -1,419.75% -26,285.71% -11,009.09% 0.00% -82,828.57% -9,437.04% -20,856.67% -762.59%
Free Cash Flow to Firm to Interest Expense		 -15.93 -49.28 -83.19 246.52 -0.41 10.65 48.47 0.00 0.00 0.00 -2,117.96
Operating Cash Flow to Interest Expense		 -27.57 -30.34 -132.74 -42.59 -60.33 -21.25 -11.26 0.00 0.00 0.00 -366.94
Operating Cash Flow Less CapEx to Interest Expense		 -27.69 -31.02 -133.91 -45.59 -60.56 -21.44 -11.21 0.00 0.00 0.00 -415.06
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.21 0.28 0.57 0.43 0.57 0.65 0.59 0.49 0.41 0.45 0.32
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.05 4.41 5.86 5.88 7.16 8.60 9.26 10.42 12.17 14.79 7.75
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -4.04 -5.93 -4.47 -13 -6.67 -9.26 -34 -3.85 -12 -8.37 -2.49
Invested Capital Turnover		 -1.04 -0.80 -1.29 -0.68 -1.07 -0.77 -0.27 -0.64 -0.58 -0.59 -0.29
Increase / (Decrease) in Invested Capital		 -0.89 0.36 0.52 -9.24 -2.63 -3.34 -29 8.92 -4.88 0.90 31
Enterprise Value (EV)		 -2.80 3.34 8.08 1.14 7.11 6.47 6.28 4.50 51 58 13
Market Capitalization		 3.86 7.92 7.72 6.29 8.61 6.78 16 11 68 70 28
Book Value per Share		 $0.91 ($0.30) ($1.13) ($1.17) ($0.88) ($1.52) ($4.01) $0.09 $0.05 $0.03 $0.07
Tangible Book Value per Share		 $0.76 ($0.39) ($1.23) ($1.32) ($1.03) ($1.66) ($4.15) $0.07 $0.04 $0.02 $0.07
Total Capital		 6.97 2.63 -1.25 -4.33 -1.88 -5.66 -24 3.03 5.05 4.75 13
Total Debt		 4.35 3.98 3.59 3.29 3.29 3.29 0.00 0.00 0.00 0.75 0.67
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -6.66 -4.58 0.37 -5.14 -1.50 -0.31 -9.87 -6.88 -17 -12 -14
Capital Expenditures (CapEx)		 0.01 0.04 0.04 0.08 0.01 0.01 -0.03 0.01 0.03 0.03 0.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.61 -5.47 -5.82 -15 -8.24 -11 -9.56 -4.98 -13 -9.51 -4.37
Debt-free Net Working Capital (DFNWC)		 5.39 3.08 -2.60 -6.12 -3.46 -7.00 0.31 1.90 3.97 3.61 11
Net Working Capital (NWC)		 1.05 -0.89 -6.19 -9.41 -6.75 -10 0.31 1.90 3.97 2.86 10
Net Nonoperating Expense (NNE)		 0.94 1.11 0.95 0.35 0.21 1.17 15 -6.69 1.29 1.69 1.96
Net Nonoperating Obligations (NNO)		 -6.66 -4.58 0.37 -5.14 -1.50 -0.31 -9.87 -6.88 -17 -12 -14
Total Depreciation and Amortization (D&A)		 0.23 0.10 0.17 0.15 0.15 0.29 0.18 0.06 0.08 0.16 0.09
Debt-free, Cash-free Net Working Capital to Revenue		 -149.61% -111.36% -95.66% -264.11% -144.00% -182.11% -183.60% -93.68% -240.22% -182.39% -84.41%
Debt-free Net Working Capital to Revenue		 143.80% 62.75% -42.67% -111.00% -60.37% -120.19% 5.94% 35.70% 75.50% 69.17% 207.26%
Net Working Capital to Revenue		 27.89% -18.18% -101.68% -170.76% -117.87% -176.72% 5.94% 35.70% 75.50% 54.79% 194.38%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.00) ($1.21) ($0.75) ($0.45) ($0.37) ($14.75) ($29.75) $0.02 ($0.04) $23.00 ($1.05)
Adjusted Weighted Average Basic Shares Outstanding		 3.23M 3.14M 4.32M 6.50M 7.86M 265.61K 582.67K 48.39M 107.43M 3.11M 6.65M
Adjusted Diluted Earnings per Share		 ($1.00) ($1.21) ($0.75) ($0.71) ($0.37) ($14.75) ($29.75) ($0.01) ($0.04) $23.75 ($1.05)
Adjusted Weighted Average Diluted Shares Outstanding		 3.23M 3.14M 4.32M 10.74M 7.86M 308.03K 582.67K 209.15M 107.43M 3.11M 6.65M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.21) $0.00 $0.00 $0.00 ($14.75) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.52M 4.28M 0.00 5.90M 5.90M 679.99K 1.31M 99.26M 137.43M 6.86M 6.88M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.28 -2.70 -2.31 -2.59 -2.66 -2.73 -2.48 -1.08 -3.14 -4.02 -4.98
Normalized NOPAT Margin		 -183.52% -205.68% -137.70% -202.34% -182.64% -193.34% -233.73% -77.45% -224.58% -294.03% -484.76%
Pre Tax Income Margin		 -259.60% -290.18% -194.45% -229.87% -197.39% -276.42% -1,643.15% 370.58% -316.61% -417.92% -675.68%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -37.37 -62.23 -97.03 -110.37 -47.43 -68.42 -30.76 0.00 0.00 0.00 -418.76
NOPAT to Interest Expense		 -26.16 -43.56 -67.92 -95.85 -43.60 -47.89 -4.52 0.00 0.00 0.00 -293.14
EBIT Less CapEx to Interest Expense		 -37.48 -62.90 -98.21 -113.37 -47.66 -68.61 -30.71 0.00 0.00 0.00 -466.88
NOPAT Less CapEx to Interest Expense		 -26.27 -44.24 -69.10 -98.85 -43.82 -48.09 -4.47 0.00 0.00 0.00 -341.25
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -3.56% -7.20% -6.75% -6.58% -2.88% 0.00% -0.92% -1.12% -1.03% -13.36%

Financials Breakdown Chart

Plus Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Plus Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

In the past 10 years, Plus Therapeutics' net income has ranged from -$22.69 million in 2017 to -$8.24 million in 2020, and is currently -$22.39 million as of their latest financial filing in 2025. Check out Plus Therapeutics' forecast to explore projected trends and price targets.

Plus Therapeutics' total operating income in 2025 was -$15.30 million, based on the following breakdown:
  • Total Gross Profit: $5.21 million
  • Total Operating Expenses: $20.51 million

Over the last 10 years, Plus Therapeutics' total revenue changed from $4.84 million in 2015 to $5.21 million in 2025, a change of 7.8%.

Plus Therapeutics' total liabilities were at $12.33 million at the end of 2025, a 20.9% decrease from 2024, and a 51.6% decrease since 2015.

In the past 10 years, Plus Therapeutics' cash and equivalents has ranged from $76 thousand in 2024 to $18.40 million in 2021, and is currently $4.26 million as of their latest financial filing in 2025.

Over the last 10 years, Plus Therapeutics' book value per share changed from 0.08 in 2015 to 0.03 in 2025, a change of -62.2%.


Related Companies

Financial statements for NASDAQ:PSTV last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel